Poll shows most Russians frown on TV host-turned-presidential contender SobchakSociety & Culture October 19, 13:26
Micro-computer glitch behind delayed launch of Russia’s Progress cargo spacecraftScience & Space October 19, 13:17
Moscow cautious about NATO’s growing presence in Baltic regionRussian Politics & Diplomacy October 19, 13:16
South Korean diplomat to visit Moscow to discuss North KoreaWorld October 19, 13:04
Press review: Reality TV host to challenge Putin and Iran helps Iraq to retake KirkukPress Review October 19, 13:00
Ground infrastructure for Baiterek space rocket compound may cost $300 mlnScience & Space October 19, 12:59
Plaintiffs in Russian A321 jet crash over Sinai file 1.4 bln euro lawsuitWorld October 19, 12:58
Veteran Russian legislator slams Sobchak as ‘fake’ presidential contenderRussian Politics & Diplomacy October 19, 12:30
Romano Prodi says sanctions against Moscow damage EU-Russian relationsWorld October 19, 12:19
KALUGA, April 10. /TASS/. Novo Nordisk, a Danish global healthcare company specializing in diabetes care, announced on Friday the opening of an insulin manufacturing facility in central Russia’s Kaluga region.
Hans Kennet Mortensen, branch director of Kaluga Novo Nordisk, told TASS that the total sum of investment into the manufacturing site amounted to $100 million, but declined to specify the projected volume of insulin production there on grounds of commercial confidentiality.
A statement posted on the company’s official website on Friday said the new facility would focus on the production of insulin cartridges and prefilled insulin injection pens for distribution on Russia's market.
"The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies," Novo Nordisk CEO Lars Rebien Sorensen said on the site.
"With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day," Sorensen added.
Anatoly Artamonov, Kaluga region governor, said 450 million euro ($477.8 million) was being invested to form a pharmaceuticals cluster in the region, planned to produce 12% of all pharmaceutical supplies for the Russian market by 2020.
"Opening of Novo Nordisk's manufacturing facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga," Artamonov said.
"I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia."
Novo Nordisk, headquartered in Denmark, is a global healthcare company with 90 years of innovation and leadership in diabetes care. According to the company’s official reference material, Novo Nordisk "also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy".
Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.